REG - Syncona Limited - Notice of Results

SynconaAnnouncement

18/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241018:nRSR6765Ia&default-theme=true

RNS Number : 6765I  Syncona Limited  18 October 2024

18 October 2024

 

Syncona Limited

 

Notice of Interim Results

 

Syncona Ltd, ("Syncona" or the "Company") a leading life science investor
focused on creating, building and scaling global leaders in life science, will
announce its interim results for the period ended 30 September 2024 on
Thursday 14 November 2024.

 

An in-person presentation for analysts will take place at 09.00am GMT, with a
webcast available on the Company's website at
https://www.synconaltd.com/investors/results-and-presentations/
(https://www.synconaltd.com/investors/results-and-presentations/) or via this
link
(https://sparklive.lseg.com/SynconaLtd/events/e6853198-bdca-4115-af91-fcff433ead69/syncona-interim-results-2024)
.

 

 

 ENDS 

 

Enquiries

 

Syncona Ltd

 

Natalie Garland-Collins / Fergus Witt

Tel: +44 (0) 20 3981 7912

 

FTI Consulting

 

Ben Atwell / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

About Syncona

 

Syncona's purpose is to invest to extend and enhance human life. We do this by
creating, building and scaling companies to deliver transformational
treatments to patients in areas of high unmet need.

We aim to build and maintain a diversified portfolio of 20-25 globally leading
life science businesses, across development stage, modality and therapeutic
area, for the benefit of all our stakeholders. We focus on developing
treatments that deliver patient impact by working in close partnership with
world-class academic founders and experienced management teams. Our balance
sheet underpins our strategy, enabling us to take a long-term view as we look
to improve the lives of patients with no or poor treatment options, build
sustainable life science companies and deliver strong risk-adjusted returns to
shareholders.

Syncona Limited seeks to achieve returns over the long term. Investors should
seek to ensure they understand the risks and opportunities of an investment in
Syncona Limited, including the information in our published documentation,
before investing.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORQKOBDOBDDFKD